Audit Committee 

To enhance the supervisory functions and strengthen management capabilities, the Company's shareholders' meeting elected four independent directors on May 28, 2024. In accordance with the Securities and Exchange Act, the Board of Directors has established an Audit Committee under the Board. The Audit Committee is composed of all independent directors. The main purposes of the Audit Committee's operations are to oversee the fair presentation of the Company's financial statements, the selection/dismissal, independence, and performance of the certified public accountants, the effective implementation of the Company's internal controls, compliance with relevant laws and regulations, and the management of existing or potential risks faced by the Company. 
 

Key focus areas of the Audit Committee in 2024

--Review of financial reports. 
--Review of internal control systems and related policies and procedures. 
--Review of the effectiveness of internal control systems. 
--Review of legal compliance. 
--Review of material assets or derivative transactions. 
--Review of derivative financial instruments and cash investment situations. 
--Review of fundraising or issuance of securities. 
--Review of related-party transactions and potential conflicts of interest involving managers and directors. 
--Review of the appointment, dismissal, and independence of certified public accountants. 
--Review of the appointment or dismissal of financial, accounting, or internal audit supervisors. 
--Performance of the Audit Committee's duties. 
--Self-assessment questionnaires on Audit Committee performance. 
 

The Audit Committee meets at least once per quarter. 

Current term:  2024/05/28 to 2027/05/27 
Name  Role  Education & Experience  Current Position 
Pei-Wei Chen 

Convener & 

Independent Director  

  • M.Acc., National Chung Cheng University  
  • Deputy Manager, Deloitte Touche Tohmatsu CPA Ltd. 
  • CPA, Solomon & Co., CPAs 
  • Lecturer, Department of Accounting, Chungyu Institue of Technology 
  • Lecturer, National Taipei College of Business 
  • CPA, Wei Chuang CPA Firm 
  • CPA, Weide CPAs. 
  • Director, Chun Chuang Wealth Management Consulting Co., Ltd. 
  • Independent Director, Les enphants Co., Ltd. 
Shui-Ming Chuang  Independent Director 
  • LL.B., Department of Law, National Taiwan University
  • Prosecutor, Taiwan Taipei District Prosecutors Office
  • Prosecutor, Taiwan Kaohsiung District Prosecutors Office 
  • Judge, Taiwan Taipei District Court 
  • Judge, Taiwan Banqiao District Court 
  • CEO, Public Health and Liver Disease Prevention and Control Promotion, Liver Disease Prevention and Treatment Research Foundation 
Sheue-Rong Lin  Independent Director 
  • B.A., Public Health, National Taiwan University
  • M.A., Epidemiology Research, Johns Hopkins University 
  • Doctoral research in Epidemiology, National Taiwan University 
  • Director/Division Chief, Centers for Disease Control, Ministry of Health and Welfare 
  • Director, Taoyuan County Health Bureau 
  • Director, Food Hygiene Division, Department of Health, Executive Yuan 
  • Deputy Director-General, Food and Drug Administration, Department of Health, Executive Yuan 
  • Counselor, Department of Health, Executive Yuan
  • Director, New Taipei City Health Bureau 
  • CEO, Public Health and Liver Disease Prevention and Control Promotion, Liver Disease Prevention and Treatment Research Foundation 
Jou-Kou Wang  Independent Director 
  • Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
  • EMBA, Graduate Institute of Business Administration, National Taiwan University
  • Deputy Superintendent, National Taiwan University Hospital 
  • Professor, Department of Pediatrics, College of Medicine, National Taiwan University 
  • Director, Division of Pediatric Cardiology, National Taiwan University Hospital 
  • Director, Division of Pediatric Cardiology, National Taiwan University Hospital 
  • Director/Supervisor, Taiwan Society of Cardiology
  • Independent Director, AnTai Technology Co., Ltd 
 

Audit Committee Meeting Attendance 

Role  Name  Meetings Attended  Attendance Rate (%) Remarks
Chair  Pei-Wei Chen  5 100.00% Re-elected on 2024/5/28
Member  Bo-Hsiung Lai  3 100.00% Re-elected on 2024/5/28 
Member  Shui-Ming Chuang  5 100.00% Re-elected on 2024/5/28 
Member  Sheue-Rong Lin  5 100.00% Re-elected on 2024/5/28 
Member  Jou-Kou Wang  2 100.00% Newly appointed on 2024/5/28 

Additional Notes
I. If the Audit Committee experiences any of the following situations, details must be disclosed, including meeting date, session number, agenda items, independent directors' objections, reservations, or major recommendations, the resolution results, and how the Company addressed the Committee's opinions.
1. Matters listed in Article 14-5 of the Securities and Exchange Act – see the table below. 
2. Other matters not approved by the Audit Committee but passed by more than two-thirds of all directors – see the table below. 
 

Additional Notes 

I. Matters under Article 14-5 of the Securities and Exchange Act:
Date  Agenda Items  Article 14-5 of the
Securities and
Exchange Act 
Not Approved by
Audit Committee but
Passed by ≥ 2/3 of Board 
2024/01/30
  1. Proposal for strategic alliance with Taiwan Exosome Corp. 
Compliant
None
2024/03/11
  1. 2023 Internal Control System Statement. 
  2. 2023 Business Report and Financial Statements. 
  3. 2023 Loss Appropriation Table. 
  4. CPA Independence and Competence Evaluation. 
  5. Partial amendments to Audit Committee Charter. 
Compliant
None
2024/05/10
  1. Q1 2024 Consolidated Financial Statements. 
  2. 2024 Pre-approved General Principles for Non-assurance Services. 
Compliant
None
2024/08/09
  1. Q2 2024 Consolidated Financial Statements.  
  2. Change of Chief Accounting Office 
Compliant
None
2024/11/05
  1. Q3 2024 Consolidated Financial Statements.
  2. New Internal Control System and Audit Implementation Rules for “Sustainability Information Management.”  
  3. 2025 Annual Audit Plan. 
  4. Amendment to strategic alliance agreement for oncolytic virus drug OBP-301 (Telomelysin) with Oncolys BioPharma, Japan.
Compliant
None

II. Execution of Recusal by Independent Directors for Related-party Proposals:The disclosure shall include the names of the independent directors, the content of the proposals, the reasons for recusal, and their voting status. No such cases occurred.
 
Communication Details